Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

AC Immune SA (IMR) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Aci-19764 At Dose A1, Aci-19764 At Dose A2, Aci-19764 At Dose A3, Aci-19764 At Dose A4, Aci-19764 At Dose A5, Aci-19764 At Dose A6, Aci-19764 At Dose B1, Aci-19764 At Dose B2, Aci-19764 At Dose B3, Aci-19764 At Dose C1Healthy Participants, Obesity, Type 2 Diabetes Mellitus (T2dm)Phase IRecruitingA Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk FactorsFeb 18, 2026
[18F]Aci-19626Amyotrophic Lateral Sclerosis (Als), Alzheimer's Disease (Ad), Frontotemporal Dementia (Ftd), Tdp-43 Proteinopathies, Suspected Limbic Predominant Age-Related Tdp-43 Encephalopathy (Late)earlyPhase1Recruiting[18F]ACI-19626 PET in TDP-43 ProteinopathiesMar 18, 2025
[18F]Aci-15916Parkinson's Disease (Pd), Multiple System Atrophy (Msa), Dementia With Lewy Bodies (Dlb)earlyPhase1Recruiting[18F]ACI-15916 PET in α-synucleinopathiesMar 18, 2025
Aci-7104.056 At Dose A, Aci-7104.056 At Dose B, Aci-7104.056 At Dose CParkinson Disease, Parkinson Disease 6, Early-OnsetPhase IIActive Not RecruitingA Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's DiseaseAug 04, 2023―
Aci-24.060 At Dose A, Aci-24.060 At Dose B, Aci-24.060 At Dose C, Aci-24.060 At Dose D, Aci-24.060 At Dose X, Aci-24.060 At Dose YAlzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease In Down Syndromephase1AndPhase2RecruitingA Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)Jul 12, 2022
Aci-35.030, Jaci-35.054Alzheimer's Disease, Dementia, Mild Cognitive Impairment, Cognitive Impairment, Brain Diseases, Central Nervous System Diseases, Tauopathiesphase1AndPhase2CompletedA Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's DiseaseJun 22, 2020―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does AC Immune (DE:IMR) have in its pipeline
AC Immune SA DE:IMR is currently developing the following drugs: Aci-19764 At Dose A1, Aci-19764 At Dose A2, Aci-19764 At Dose A3, Aci-19764 At Dose A4, Aci-19764 At Dose A5, Aci-19764 At Dose A6, Aci-19764 At Dose B1, Aci-19764 At Dose B2, Aci-19764 At Dose B3, Aci-19764 At Dose C1, [18F]Aci-19626, [18F]Aci-15916, Aci-7104.056 At Dose A, Aci-7104.056 At Dose B, Aci-7104.056 At Dose C, Aci-24.060 At Dose A, Aci-24.060 At Dose B, Aci-24.060 At Dose C, Aci-24.060 At Dose D, Aci-24.060 At Dose X, Aci-24.060 At Dose Y, Aci-35.030, Jaci-35.054. These drug candidates are in various stages of clinical development as the company works toward FDA approval.